Quarterly ResultAug 4, 2026, 06:12 AM
Lipocine Q2 Net Loss $2.6M; PPD Phase 3 Primary Endpoint Not Met
AI Summary
Lipocine Inc. announced its financial results for the second quarter ended June 30, 2026, reporting a net loss of $2.6 million, or ($0.32) per diluted share. The company's cash position significantly improved to $23.3 million. A major update included the Phase 3 trial for LPCN 1154 (BRLIZIO™) for Postpartum Depression not meeting its primary endpoint, though a post hoc analysis showed positive results after excluding an outlier site. Lipocine is pursuing further development with a new trial and an FDA meeting, while also expanding its pipeline for other indications and TLANDO's international reach.
Key Highlights
- Net loss for Q2 2026 was $2.6 million, or ($0.32) per diluted share, compared to $2.2 million, or ($0.41) per diluted share, in Q2 2025.
- Cash, cash equivalents, and marketable investment securities totaled $23.3 million as of June 30, 2026, up from $14.9 million at December 31, 2025.
- LPCN 1154 (BRLIZIO™) Phase 3 trial for Postpartum Depression (PPD) did not meet its primary endpoint.
- Post hoc analysis of PPD trial data, excluding an outlier site, showed clinically meaningful improvement in depression symptoms.
- FDA guidance meeting for LPCN 1154 is scheduled for Q3 2026, and a new placebo-controlled trial has been initiated.
- Royalty revenue from TLANDO sales increased to $190,000 in Q2 2026 from $123,000 in Q2 2025.
- Pharmalink received marketing authorization for TESTYRA® (TLANDO) in the UAE on July 8, 2026.
- Plans to submit Phase 2 protocols to the FDA for LPCN 2201 (Major Depressive Disorder) and LPCN 2203 (Essential Tremor).
Price Impact
More from LPCN